On 29 May 2023, Peduli Hati, the Director General of Pharmaceutical and Medical Devices, and representatives of the Communication and Public Service Bureau and the Indonesian CDC discussed procurement of additional hepatitis C medicines and rapid molecular testing machines using the national Global Fund budget.
Action taken: By July 2023, there was an agreement to procure the below medicines and machines for the national hepatitis treatment program.
- For 2023: 8,978 bottles of sofosbuvir/daclatasvir for 2023 @ $24 per bottle.
- For 2023: 50 rapid molecular testing machines to be jointly used by HIV and hepatitis programs costing $30,224 per machine
- For 2024 to 2026: 4,600 bottles per year of sofosbuvir/daclatasvir @ $24 per bottle